In a case series report involving NSCLC, 88.2% of patients received anti‐PD‐1 inhibitor treatment prior to anti‐PD‐L1 inhibitor treatment, and 29.4% received treatment after anti‐PD‐L1 inhibitor treatment; among them, four patients received a third ICI treatment (33). This evidence concerns the gene CD274 and non-small cell lung carcinoma.